Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127019 | 0.85 | GAA (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL12062913 | 0.85 | ALDH1A1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL334348 | 0.85 | GAA (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL30096935 | 0.85 | GAA (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL10309764 | 0.84 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13014917 | 0.84 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13211726 | 0.84 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL14712149 | 0.84 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3759057 | 0.84 | GAA (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3213276 | 0.84 | ALDH1A1 (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414435-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200317698-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| EP-2943204-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10125152-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-10093685-B2 | — | — | 2018-10-09 | — | — | US | disclosed |
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9771382-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9562167-B2 | Magnetic recording medium and magnetic coating composition for magnetic recording medium | FUJIFILM CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160304539-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-9403850-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-1490047-B1 | CERTAIN PHARMACEUTICALLY USEFUL SUBSTITUTED AMINOALKYL HETEROCYCLES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009107799-A1 | PROCESS FOR PRODUCTION OF THIOPHENE COMPOUND AND INTERMEDIATE THEREOF | 日産化学工業株式会社 (JP) | 2009-09-03 | — | — | WO | disclosed |
| US-6872748-B2 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | DIGITAL BIOTECH CO., LTD. (KR) | 2005-03-29 | — | — | US | disclosed |
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | MEDIFRON DBT CO., LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
| WO-2003027064-A1 | SIMPLIFIED RESINIFERATOXIN ANALOGUES AS VANILLOID RECEPTOR AGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL CO MPOSITIONS CONTAINING THE SAME | DIGITAL BIOTECH CO. LTD,. (KR) | 2003-04-03 | — | — | WO | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| EP-0505376-B1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 1994-12-07 | — | — | EP | disclosed |
| US-5340831-A | Muscarinic receptor antagonists | PFIZER INC. (US) | 1994-08-23 | — | — | US | disclosed |
| EP-0505376-A1 | MUSCARINIC RECEPTOR ANTAGONISTS. | PFIZER LTD (GB) | 1992-09-30 | — | — | EP | disclosed |
| WO-1991009013-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | NPC1 4491/4885RAB9A 1933/4885SMN1; SMN2 2444/4885 |
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | TRPV1, OPRL1, GPR180 | NPC1 3752/4885RAB9A 622/4885SMN1; SMN2 963/4885 |
| US-10093685-B2 | — | MRPL21, GAA, MGAM | NPC1 4343/4885RAB9A 1592/4885SMN1; SMN2 1473/4885 |
| US-10125152-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | NPC1 4491/4885RAB9A 1933/4885SMN1; SMN2 2444/4885 |
| US-20200317698-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | NPC1 4491/4885RAB9A 1933/4885SMN1; SMN2 2444/4885 |
| US-11414435-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | NPC1 4491/4885RAB9A 1933/4885SMN1; SMN2 2444/4885 |
| US-20160304539-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | NPC1 4491/4885RAB9A 1933/4885SMN1; SMN2 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.